Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.